Physician profile
Daranay Orta
NPI 1275176802
$882.57
in general payments reported to CMS, 2019-2025
16 companies · $180 in 2025
The $180 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $128 · 2022: $12.07 · 2023: $336 · 2024: $226 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $742.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $179.66 | 2023-2024 | Verzenio |
| American Regent | $129.24 | 2025 | Injectafer |
| Pharmacyclics LLC, An Abbvie Company | $122.97 | 2023 | Imbruvica |
| Janssen Biotech, INC. | $90.59 | 2021 | |
| Gilead Sciences, INC. | $67.26 | 2024 | |
| Daiichi Sankyo INC. | $48.85 | 2023-2024 | Enhertu |
| Pfizer INC. | $48.03 | 2021-2025 | |
| Pharmacosmos Therapeutics INC. | $32.11 | 2024 | Monoferric |
| Merck Sharp & Dohme LLC | $27.26 | 2023 | Keytruda |
| Genzyme Corporation | $26.67 | 2025 | |
| Stemline Therapeutics INC. | $24.80 | 2024 | Orserdu |
| Eisai INC. | $21.89 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $18.65 | 2024 | Enhertu |
| Puma Biotechnology, INC. | $18.45 | 2024 | |
| Incyte Corporation | $14.07 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daranay Orta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.